Population pharmacokinetics, safety and dosing optimization of voriconazole in patients with liver dysfunction: A prospective observational study
Dan Tang(Wenzhou Medical University), Daxiong Xiang(Central South University), Guozhong Gong(Central South University), Feng Wang(Central South University), Xi‐jing Chen(China Pharmaceutical University), Bikui Zhang(Central South University), Yi Tian(Central South University), Wu Liang(Valve (United States)), Yi‐Chang Zhao(Central South University), Min Zhang(Wuhan Children's Hospital), Wenlong Wang(Binzhou University), Miao Yan(Central South University), Baili Song(China Pharmaceutical University), Yongfang Jiang(Central South University), Yiwen Xiao(Central South University), Jianjun Zou(Jiangsu Hengrui Medicine (China))
Cited by 54
Related Papers
Psychological impacts and coping strategies of front-line medical staff during COVID-19 outbreak in Hunan, China
|Medical Science Monitor|2020|784
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|508
Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial
|Journal of Thoracic Oncology|2021|311
Glycated Proteins Stimulate Reactive Oxygen Species Production in Cardiac Myocytes
|Circulation|2006|186